GlassScriptPhysician profile
Mohammad Mahboob
NPI 1164429924
$5,236.07
in general payments reported to CMS, 2019-2025
31 companies · $13.89 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $741 · 2021: $1,301 · 2022: $1,168 · 2023: $756 · 2024: $16.25 · 2025: $13.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $904.37 | 2019-2025 | Breztri |
| Glaxosmithkline, LLC. | $816.64 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.70 | 2019-2023 | Ofev, Stiolto Respimat |
| Jazz Pharmaceuticals INC. | $498.53 | 2019-2022 | |
| Grifols USA, LLC | $275.35 | 2019-2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $242.67 | 2019-2023 | Yupelri |
| Axsome Therapeutics, INC. | $210.62 | 2022-2023 | Sunosi |
| United Therapeutics Corporation | $194.28 | 2021-2023 | Tyvaso |
| Sunovion Pharmaceuticals INC. | $188.02 | 2019-2021 | |
| Genentech USA, INC. | $182.12 | 2019-2023 | Xolair, Esbriet |
| Amgen INC. | $179.26 | 2021-2022 | |
| Baxter Healthcare | $156.25 | 2022-2023 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Harmony Biosciences LLC | $150.84 | 2020-2023 | Wakix |
| Genzyme Corporation | $123.19 | 2019-2022 | |
| Electromed, INC. | $100.81 | 2019-2024 | Smartvest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $70.27 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.54 | 2022-2023 | Glassia |
| Janssen Pharmaceuticals, INC | $54.40 | 2021-2022 | |
| Inogen, INC. | $44.70 | 2022-2023 | Inogen |
| Astellas Pharma US INC | $42.99 | 2019-2022 | |
| Advanced Respiratory, INC | $37.36 | 2019-2020 | |
| Eisai INC. | $34.62 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $24.63 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.28 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.15 | 2019 | |
| Philips North America LLC | $18.94 | 2021 | |
| Circassia INC. | $16.70 | 2019 | |
| Merck Sharp & Dohme LLC | $16.20 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $15.64 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.26 | 2021 | |
| Mayne Pharma Commercial LLC | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Mahboob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.